Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms.

Chronic hepatitis C (CHC) patients often stop pursuing interferon-alfa and ribavirin (IFN-alfa/RBV) treatment because of the high cost and associated adverse effects. It is highly desirable, both clinically and economically, to establish tools to distinguish responders from nonresponders and to predict possible outcomes of the IFN-alfa/RBV treatments. Single nucleotide polymorphisms (SNPs) can be used to understand the relationship between genetic inheritance and IFN-alfa/RBV therapeutic response. The aim in this study was to establish a predictive model based on a pharmacogenomic approach. Our study population comprised Taiwanese patients with CHC who were recruited from multiple sites in Taiwan. The genotyping data was generated in the high-throughput genomics lab of Vita Genomics, Inc. With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons. Our data revealed that the MFNN models were superior to the logistic regression model. The MFNN approach provides an efficient way to develop a tool for distinguishing responders from nonresponders prior to treatments. Our preliminary results demonstrated that the MFNN algorithm is effective for deriving models for pharmacogenomics studies and for providing the link from clinical factors such as SNPs to the responsiveness of IFN-alfa/RBV in clinical association studies in pharmacogenomics.

[1]  J. Blackwell.  Management of chronic hepatitis C. , 2005, Journal of the American Academy of Nurse Practitioners.

[2]  R. Erb,et al.  Introduction to Backpropagation Neural Network Computation , 1993, Pharmaceutical Research.

[3]  Ding-Shinn Chen,et al.  Genetic predisposition of responsiveness to therapy for chronic hepatitis C. , 2006, Pharmacogenomics.

[4]  Eduardo D. Sontag,et al.  Feedback Stabilization Using Two-Hidden-Layer Nets , 1991, 1991 American Control Conference.

[5]  Enrico Smeraldi,et al.  Neural network analysis in pharmacogenetics of mood disorders , 2004, BMC Medical Genetics.

[6]  M. Hijikata,et al.  Identification of a Single Nucleotide Polymorphism in the MxA Gene Promoter (G/T at nt –88) Correlated with the Response of Hepatitis C Patients to Interferon , 2000, Intervirology.

[7]  F. Schaffner.  Management of Chronic Hepatitis , 1985, Seminars in liver disease.

[8]  N. Hayashi,et al.  A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C , 2002, Journal of viral hepatitis.

[9]  Robert Fullér,et al.  Neural Fuzzy Systems , 1995 .

[10]  E. Lin,et al.  Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. , 2007, Pharmacogenomics.

[11]  Ian Witten,et al.  Data Mining , 2000 .

[12]  Heekuck Oh,et al.  Neural Networks for Pattern Recognition , 1993, Adv. Comput..

[13]  H. Mcdonald,et al.  Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. , 2005, JAMA.

[14]  Halbert White,et al.  Connectionist nonparametric regression: Multilayer feedforward networks can learn arbitrary mappings , 1990, Neural Networks.

[15]  Mohammad Ghodsi,et al.  Comparison of artificial neural network and logistic regression models for prediction of mortality in head trauma based on initial clinical data , 2005, BMC Medical Informatics Decis. Mak..

[16]  Ron Kohavi,et al.  Wrappers for Feature Subset Selection , 1997, Artif. Intell..

[17]  E. Lin,et al.  Pattern-recognition techniques with haplotype analysis in pharmacogenomics. , 2007, Pharmacogenomics.

[18]  Jenq-Neng Hwang,et al.  Neural networks for intelligent multimedia processing , 1998 .

[19]  T. Liang,et al.  Hepatitis C: a clinical review. , 2007, Oral diseases.

[20]  A. H. Piray,et al.  A comparison of artificial neural networks with other statistical approaches , 2010 .

[21]  LarrañagaPedro,et al.  A review of feature selection techniques in bioinformatics , 2007 .

[22]  L. Hayden,et al.  Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2011 .

[23]  R. Kaslow,et al.  Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection , 2001, Hepatology.

[24]  Geoffrey E. Hinton,et al.  Learning internal representations by error propagation , 1986 .

[25]  J. Kostman.  Management of chronic hepatitis. , 1971, Lancet.

[26]  Eugene Lin,et al.  Modeling short-term antidepressant responsiveness with artificial neural networks , 2010 .

[27]  Phongphun Kijsanayothin,et al.  Tumor classification ranking from microarray data , 2008, BMC Genomics.

[28]  E. Balas,et al.  Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success , 2005, BMJ : British Medical Journal.

[29]  Pedro Larrañaga,et al.  A review of feature selection techniques in bioinformatics , 2007, Bioinform..

[30]  Tom Fawcett,et al.  An introduction to ROC analysis , 2006, Pattern Recognit. Lett..

[31]  Eugene Lin,et al.  An artificial neural network approach to the drug efficacy of interferon treatments. , 2006, Pharmacogenomics.

[32]  E. Lin,et al.  A Support Vector Machine Approach to Assess Drug Efficacy of Interferon-α and Ribavirin Combination Therapy , 2012, Molecular Diagnosis & Therapy.

[33]  Eugene Lin,et al.  A comparison of classification methods for predicting Chronic Fatigue Syndrome based on genetic data , 2009, Journal of Translational Medicine.

[34]  Thomas H. Payne,et al.  Review Paper: Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review , 2007, J. Am. Medical Informatics Assoc..